SCHEMBL24710847

SCHEMBL24710847

Cc1ccc(-c2nc3ccccc3s2)cc1NC(=O)c1cc(I)ccc1Cl

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.74
▸ KMT2A Q03164 7/20 0.74
▸ ALDH1A1 P00352 7/20 0.74
▸ KDM4E B2RXH2 5/20 0.74
▸ CYP3A4 P08684 4/20 0.74
▸ CYP2C9 P11712 4/20 0.74
▸ CYP1A2 P05177 3/20 0.74
▸ CYP2C19 P33261 3/20 0.74
▸ DUSP3 P51452 3/20 0.74
▸ POLB P06746 3/20 0.74
▸ PTPN7 P35236 1/20 0.74
▸ MAPT P10636 8/20 0.71
▸ TP53 P04637 3/20 0.69
▸ NPSR1 Q6W5P4 2/20 0.58
▸ HPGD P15428 2/20 0.58
▸ SMN1; SMN2 Q16637 7/20 0.57
▸ LMNA P02545 3/20 0.57
▸ RXFP1 Q9HBX9 3/20 0.56
▸ THRB P10828 1/20 0.56
▸ BLM P54132 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16602324 0.84 TP53 (0.75) MEN1KMT2AALDH1A1KDM4ECYP3A4
SCHEMBL12963193 0.84 MEN1 (0.72) MEN1KMT2AALDH1A1KDM4ECYP3A4
SCHEMBL12963427 0.84 MAPT (0.70) MEN1KMT2AALDH1A1KDM4ECYP3A4
SCHEMBL12963192 0.83 TP53 (0.69) MEN1KMT2AALDH1A1KDM4ECYP3A4
SCHEMBL12963202 0.82 TP53 (0.71) MEN1KMT2AALDH1A1KDM4ECYP3A4
SCHEMBL12963458 0.80 SMN1; SMN2 (0.85) MEN1KMT2AALDH1A1KDM4ECYP3A4
SCHEMBL24711450 0.80 MAPT (0.69) MEN1KMT2AALDH1A1KDM4ECYP3A4
SCHEMBL12981158 0.78 MAPT (0.71) MEN1KMT2AALDH1A1KDM4ECYP3A4
SCHEMBL12963468 0.78 MAPT (0.76) MEN1KMT2AALDH1A1KDM4ECYP3A4
SCHEMBL13173972 0.78 MAPT (0.78) MEN1KMT2AALDH1A1KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF NEURALEXO, INC. 2022-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF IRF3, IRF2BP2, STAT1 MEN1 4664/4885KMT2A 3862/4885ALDH1A1 4853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback